Stockreport

Motif Bio to Present Iclaprim Data at ECCMID 2018

MOTIF BIO PLC ADRS  (MTFB) 
US:NASDAQ Investor Relations: ir.motifbio.com
PDF Phase 3 trial results for REVIVE-2 in patients with ABSSSIPotential cost savings opportunities with iclaprim versus vancomycinIclaprim in vitro susceptibility data [Read more]